Drug Trial Radar · NCT03781804
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
Last checked: Nov 19, 2026Latest source record: May 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
332
Actual
Start
Nov 27, 2018
Primary completion
Jan 19, 2022
Study completion Jan 19, 2022
Sponsor
- Lead sponsor
- Optinose US Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of intranasal administration of 186 and 372 μg twice daily (BID) of OPN-375 in subjects with chronic rhinosinusitis (CS) with or without nasal polyps.
Conditions
- Chronic Rhinosinusitis
Interventions
OPN-375Drug
OPN-375, BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior and/or Posterior) at the End of Week 4Time frame: 4 Weeks
- Change From Baseline to Week 24/Early Termination (ET) in the Average Percent of the Volume Opacified in the Ethmoid and Maxillary SinusesTime frame: Baseline, Week 24
Locations
92 sites in 8 countries. Site status is shown where the registry gives one.
AZ Allergy & Immunology Research
Gilbert, Arizona
Kern Research
Bakersfield, California
Sacramento Ear, Nose & Throat Surgical and Medical Group Inc
Folsom, California
Allergy & Asthma Specialists Medical Group
Huntington Beach, California
Jonathan Corren, MD, Clinical Research Division
Los Angeles, California
Sacramento Ear, Nose & Throat
Roseville, California
UC Davis Medical Center
Sacramento, California
Allergy and Asthma Associates of Santa Clara Valley
San Jose, California
Breathe Clear Institute
Torrance, California
Allergy & Asthma Clinical Research
Walnut Creek, California
Colorado ENT & Allergy
Colorado Springs, Colorado
Yale School of Medicine Section of Otolaryngology
New Haven, Connecticut
Emory University MOT
Atlanta, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
The University of Chicago
Chicago, Illinois
Midwest Allergy Sinus Asthma
Normal, Illinois
Advanced ENT and Allergy
New Albany, Indiana
Iowa Head & Neck
Des Moines, Iowa
Kentuckiana Ear Nose & Throat
Louisville, Kentucky
Ochsner Clinic Foundation
New Orleans, Louisiana
John Hopkins Hospital
Baltimore, Maryland
Ear, Nose and Throat Associates at Greater Baltimore Medical Center
Towson, Maryland
St. Cloud Ear, Nose & Throat
Saint Cloud, Minnesota
University of Missouri, Dept of Otorlaryngology
Columbia, Missouri
Asthma, Allergy, and Immunology Associates, PC
Lincoln, Nebraska
Atlantic Research Center
Ocean City, New Jersey
ENT and Allergy Associates
New Hyde Park, New York
Mount Sinai Downtown Union Square
New York, New York
Madison ENT and Facial Plastic Surgery
New York, New York
Allergy Asthma & Immunology Relief of Charlotte
Charlotte, North Carolina
Allergy Asthma & Clinical Research Center
Oklahoma City, Oklahoma
Vital Prospects Clinical Research Institute, P.C.
Tulsa, Oklahoma
Northwest Research Center
Portland, Oregon
Specialty Physician Associates
Bethlehem, Pennsylvania
Hospital at the University of PA
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
National Allergy and Asthma Research
North Charleston, South Carolina
Holston Medical Group
Kingsport, Tennessee
University of TX Health Science Ctr at Houston
Houston, Texas
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.